2. Search Result
Search Result
Results for "

A-22

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Biochemical Assay Reagents

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118773
    MreB Perturbing Compound A22 hydrochloride

    A22 hydrochloride

    		 Bacterial Antibiotic Inflammation/Immunology
    MreB Perturbing Compound A22 hydrochloride is a benzylisothiourea compound that interacts with the ATP binding site of MreB rapidly and reversibly. MreB Perturbing Compound A22 hydrochloride blocks normal rod shape formation and inhibits chromosome partitioning in E. coli, inhibiting growth (MIC=3.1 µg/ml).
    MreB Perturbing Compound <em>A22</em> hydrochloride
  • HY-14347
    EBE-A22

    		Others Cancer
    EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
    EBE-<em>A22</em>
  • HY-153278
    CDK7-IN-21

    		CDK Cancer
    CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor .
    CDK7-IN-21
  • HY-D1005A22
    Poloxamer 338 (F108)

    PEG-PPG-PEG, 14600 (Averag)

    		 Biochemical Assay Reagents
    Poloxamer 338 F108 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 14600. Poloxamer 338 F108 reduces the aggregation of red blood cells, inihibits proliferation of human lymphocyte cell IIBR1. Poloxamer 338 F108 exhibits short-term and subchronic toxicity in rats .
    Poloxamer 338 (F108)
  • HY-131583
    MP265

    4-Chlorobenzyl carbamimidothioate hydrochloride

    		 Others Infection
    MP265 (4-Chlorobenzyl carbamimidothioate hydrochloride) is a structural analogue of A22 but is less toxic. MP265 is a MreB inhibitor .
    MP265
  • HY-142672
    ATR-IN-6

    		ATM/ATR Cancer
    ATR-IN-6 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .
    ATR-IN-6
  • HY-155721
    22-(4′-py)-JA

    22-(4′-Pyridinecarbonyl) jorunnamycin A

    		 Akt mTOR Cancer
    22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .
    <em>22</em>-(4′-py)-JA
  • HY-RS13103
    SLC25A22 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SLC25A22 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC25A22 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SLC25A22 Human Pre-designed siRNA Set A
    SLC25A22 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: